CD47 and neoplasm: For that reason, blocking the CD47-SIRPα axis has been widely investigated in cancer treatment with the reported treatment effects being enhancement of tumor cell phagocytosis, TAM repolarization towards an M1 phenotype, increased DC mediated antigen presentation to CD4 and CD8 T cells, enhancement of NK-mediated Antibody Dependent Cellular Cytotoxicity and caspase-independent tumor cells apoptosis (168).